Chardan Capital analyst Keay Nakae reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $3.00. The company’s shares closed yesterday at $0.79.
Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Arbutus Biopharma, and Mesoblast. According to TipRanks, Nakae has an average return of -3.5% and a 33.41% success rate on recommended stocks.
SAB Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.50, which is a 216.46% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $2.00 price target.
See today’s best-performing stocks on TipRanks >>
SABS market cap is currently $39.81M and has a P/E ratio of -1.31.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
Read More on SABS:
